Research_team-NK-IO Ltd. © NK-IO Ltd

British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.

Alnylam CEO Yvonne-Greenstreet. © Alnylam Pharmaceuticals.jpg

siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T

Domain Therapeutics SA's labs in Illkirch-Graffenstaden. © Domain Therapeutics SA

The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.

Eli Lilly and Company's headquarters © Momoneymoproblemz/wikimedia com

Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.

@ Connect in Pharma

Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.

© Jackmac34/pixabay.com

Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.

Emmanuel Ladent, CEO of Carbios. © Carbios SAS

In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.

Herpes simplex vector. © EG 427

Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.

Picture: Paleo's CEO Hermes Sanctorum, CSO Elsa Lauwers, and COO Andy de Jong ©?Paleo NV

Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.

Picture: Flash Therapeutics

Toulouse-based Flash Therapeutics has appointed Jerome Bedier as its new President.